Our statistical risk expertise helps tech and healthcare companies and specialists (physicians, nurses) better detect, understand, and prevent the most complex risks.
For stakeholders in human, animal, and plant health who want to better understand the pathogenesis of adverse events, limit their impact, or improve process efficiency.
For stakeholders in human health, agriculture, and companies working on complex risks. The goal is to model these risks to anticipate them better and reduce their impact.
Oriskami SAS is an expertise office in epidemiological statistics and risk based near Rennes (35), operating under the name Direct Epidemio-Statistics.
Direct Epidemio-Statistics — Market Access Marketing Expertise
We help SMEs and innovative companies leverage precise data, model and score risks, anticipate adverse events, and create value-driven services.
RC-AVP /Addictions (psychiatrie)
RISK-SCO /Sécurité des Transports
CIR /Agrément 2022-2027
Our marketing services
At which stages of market access does Direct Epidemio-Statistics intervene?
What is our value at each stage?
AM-PRE
Feasibility study
Direct Epidemio-Statistics helps you pre-assess market access feasibility. The engagement sizes the study, anticipates risks that may jeopardize approval, and drafts an initial operational schedule. The study may include:
a preliminary project sizing
a preliminary risk assessment
a draft operational schedule
a preliminary cost-time estimate (EUR, time)
Engagement elements
completed in 2 to 6 weeks
PDF deliverable (🇬🇧 / 🇫🇷)
on-site presentation
email and phone support
Extracts / client cases
AM-AVP
Protocol design
Direct Epidemio-Statistics helps design the study targeting market authorization and strengthens your argumentation. We intervene on the following topics:
choosing the experimental design
description of the target population
description of variables to collect
cohort sizing
the epidemiological-statistical analysis plan
identification of risks and their costs
an ethical assessment of your trial project
Engagement elements
completed in 2 to 8 weeks
PDF deliverable (🇬🇧 / 🇫🇷)
on-site presentation
email and phone support
Extracts / client cases
AM-EXE
Cohort follow-up
Direct Epidemio-Statistics helps you track, over the long term, study subjects in your pre-market trials. Our scope may include:
design of questionnaires with high response rates
sending, collecting, and triaging follow-up mailings
coordination of lost-to-follow-up investigations
Engagement elements
selection criteria
study subject lists
follow-up questionnaires
feedback from mailings
coordination support
on-site visits possible
email and phone support
Questionnaire example
AM-SYN
Analysis and synthesis
Direct Epidemio-Statistics can perform the epidemiological-statistical analysis, write the methods section, suggest arguments before submission, and help address expert reviews. The scope may include:
trial description
data pre-processing
description of patient profiles
choice of statistical inference methods
model building and simulations
production of tables and charts
writing the methods and argument support
support for responses to reviewers (methods)
Engagement elements
completed in 2 to 12 weeks
PDF deliverable (🇬🇧 / 🇫🇷)
on-site presentation
email and phone support
Extracts / client cases
AM-MAR
Market access marketing
Direct Epidemio-Statistics helps you develop marketing collateral to promote your results, products, or services. The market access marketing engagement may include:
description of your R&D product
description of your individual and population profiles
production of tables and charts
writing the methods and argument support
support for responses to technical-sales questions